Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina (RENEW)

This study has been completed.
Information provided by (Responsible Party):
Baxalta US Inc. Identifier:
First received: January 10, 2012
Last updated: December 11, 2015
Last verified: December 2015